FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

Phase 1CYWC628Positive

AI Analysis

Summary

FibroBiologics reported Q2 2026 financial results and announced first patients dosed in a Phase 1/2 clinical trial evaluating CYWC628 for diabetic foot ulcers, with interim results expected in the second half of 2026.

Clinical Trial Data

Phase

1/2

Outcome Details

First patients dosed in phase 1/2 clinical trial

Importance:6/10

Sentiment:

0.60

wound careclinical trialPhase 1/2interim results expected H2 2026diabetic foot ulcers

Related Companies

$FBLG

Read the original article

Published by PR Newswire Pharma on July 31, 2026 9:34 PM

Read Original